Lv3
330 积分 2024-02-01 加入
Cost-Utility Analysis of Pazopanib Verse Sunitinib as First-Line Treatment of Metastatic Renal Cell Carcinoma (MRCC) iN Spain
1小时前
待确认
Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States
1小时前
已完结
Elicitation of health state utilities in metastatic renal cell carcinoma
5小时前
已完结
Cost-effectiveness model of renal cell carcinoma (RCC) surveillance in hereditary leiomyomatosis and renal cell carcinoma (HLRCC)
5小时前
求助中
Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea
5小时前
已完结
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
5小时前
已完结
Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma
23小时前
已完结
Cost–Effectiveness Analysis of Nivolumab Plus Cabozantinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma
1天前
已完结
Nivolumab in the treatment of metastatic renal cell carcinoma: A cost-utility analysis
1天前
求助中
Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma
1天前
已完结
皖公网安备34019202002308
